Current Treatment Options in Oncology最新文献_第3页

Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer. 激素受体阳性早期乳腺癌系统治疗的最新进展。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-10-01 Epub Date: 2024-10-03 DOI: 10.1007/s11864-024-01258-5

Emily Hsu, Sabrina M Arezo, Stephanie L Graff

{"title":"Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer.","authors":"Emily Hsu, Sabrina M Arezo, Stephanie L Graff","doi":"10.1007/s11864-024-01258-5","DOIUrl":"10.1007/s11864-024-01258-5","url":null,"abstract":"Opinion statement: Hormone-receptor positive (HR +) and human epidermal growth factor receptor 2 (HER2) negative early breast cancer (eBC) is a heterogeneous disease with several contributing factors for increased risk of recurrence, including tumor features, individual biomarkers, and genomic risk. The current standard approach in the management of HR + /HER2neg eBC includes chemotherapy and endocrine therapy (ET), and additional therapies based on risk profile, menopausal status, and genetics are sometimes appropriate. The risk of recurrence is more pronounced in patients with high-risk eBC including large tumor size, nodal involvement, high proliferative index, and genetic predisposition. In premenopausal patients with high-risk eBC, ovarian function suppression in combination with adjuvant ET improves survival. In postmenopausal patients, extended aromatase inhibitor (AI) therapy can be considered. Recent trials have identified novel treatment approaches to reduce the risk of recurrence in high-risk HR + /HER2neg eBC including the addition of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors to adjuvant ET. For patients with germline BRCA1/BRCA2 mutations, adjuvant poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have been shown to improve overall survival (OS). However, despite these recent advances, the risk of recurrence remains substantial, highlighting an area of unmet need. There are several ongoing clinical trials further investigating the role of CDK 4/6 inhibitors and immunotherapy in high-risk HR + /HER2neg eBC.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"1323-1334"},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer. FTD/TPI + 贝伐珠单抗联合疗法在不可切除转移性结直肠癌治疗中的临床试验数据回顾。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-10-01 Epub Date: 2024-09-26 DOI: 10.1007/s11864-024-01261-w

Thierry André, Eric Van Cutsem, Julien Taieb, Marwan Fakih, Gerald W Prager, Fortunato Ciardiello, Alfredo Falcone, Mark Saunders, Nadia Amellal, Lucas Roby, Josep Tabernero, Per Pfeiffer

{"title":"Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer.","authors":"Thierry André, Eric Van Cutsem, Julien Taieb, Marwan Fakih, Gerald W Prager, Fortunato Ciardiello, Alfredo Falcone, Mark Saunders, Nadia Amellal, Lucas Roby, Josep Tabernero, Per Pfeiffer","doi":"10.1007/s11864-024-01261-w","DOIUrl":"10.1007/s11864-024-01261-w","url":null,"abstract":"Opinion statement: Recommended first and second line treatments for unresectable metastatic colorectal cancer (mCRC) include fluorouracil-based chemotherapy, anti-vascular endothelial growth factor (VEGF)-based therapy, and anti-epidermal growth factor receptor-targeted therapies. In third line, the SUNLIGHT trial showed that trifluridine/tipiracil + bevacizumab (FTD/TPI + BEV) provided significant survival benefits and as such is now a recommended third line regimen in patients with refractory mCRC, irrespective of RAS mutational status and previous anti-VEGF treatment. Some patients are not candidates for intensive combination chemotherapy as first-line therapy due to age, low tumor burden, performance status and/or comorbidities. Capecitabine (CAP) + BEV is recommended in these patients. In the SOLSTICE trial, FTD/TPI + BEV as a first line regimen in patients not eligible for intensive therapy was not superior to CAP + BEV in terms of progression-free survival (PFS). However, in SOLSTICE, FTD/TPI + BEV resulted in similar PFS, overall survival, and maintenance of quality of life as CAP + BEV, with a different safety profile. FTD/TPI + BEV offers a possible first line alternative in patients for whom CAP + BEV is an unsuitable treatment. This narrative review explores and summarizes the clinical trial data on FTD/TPI + BEV.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"1312-1322"},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Nursing in the Delivery of Cardio-Oncology 护理在心外科肿瘤治疗中的作用

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-17 DOI: 10.1007/s11864-024-01241-0

Anecita Fadol, Lisa Nodzon, Geraldine Lee

{"title":"The Role of Nursing in the Delivery of Cardio-Oncology","authors":"Anecita Fadol, Lisa Nodzon, Geraldine Lee","doi":"10.1007/s11864-024-01241-0","DOIUrl":"https://doi.org/10.1007/s11864-024-01241-0","url":null,"abstract":"Nurses are the “heart of patient care” and in the forefront of the health care delivery for cardio-oncology patients. Nurses play a critical central role in maximizing longitudinal health of cancer patients and survivors through the prevention of cardiovascular complications throughout the patient’s cancer care journey. Nurses function in a variety of roles such as nurse clinicians, advanced practice nurses (APNs)or nurse practitioners (NPs), patient educators, managers, nurse navigators or nurse researchers. The role of nurses, particularly the advanced practice nurses as key members in delivering cardio-oncology care is evolving. However, despite the rapidly increasing growth of cardio oncology programs globally, a pivotal need remains to develop and provide formalized training programs for nurses, NPs and APNs. At present, no formal academic cardio-oncology nurse training program or certification exists. There is clearly more work to be done on the role of nurses in cardio-oncology care. As cardio-oncology evolves to become a key specialty with dedicated services being established across the globe, the role of the nurse in delivering this service is critical and a concerted collaborative approach between the two distinct specialties of cardiology and oncology needs to ensure the nursing workforce is educationally prepared and confident to treat and manage cardio-oncology patients.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"6 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research Progress on Ferroptosis in Multiple Myeloma 多发性骨髓瘤中的铁蛋白沉积研究进展

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-17 DOI: 10.1007/s11864-024-01250-z

Po Li, Tianxin Lyu

引用次数: 0

Myeloproliferative Neoplasms and Cardiovascular Disease: A Review 骨髓增生性肿瘤与心血管疾病：综述

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-16 DOI: 10.1007/s11864-024-01255-8

Orly Leiva, Olivia Liu, Sophia Zhou, Joan How, Michelle Lee, Gabriela Hobbs

引用次数: 0

The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy 晚期肝细胞癌的治疗趋势：免疫疗法与靶向疗法相结合

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-11 DOI: 10.1007/s11864-024-01246-9

Heng Dong, Zhengguo Zhang, Mengjie Ni, Xiaoyun Xu, Yifeng Luo, Yaru Wang, Haiyun Zhang, Jianxiang Chen

引用次数: 0

Management Approaches for High-Risk Cutaneous Squamous Cell Carcinoma with Perineural Invasion: An Updated Review. 高风险皮肤鳞状细胞癌伴有神经周围侵犯的处理方法：最新综述。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-01 Epub Date: 2024-08-05 DOI: 10.1007/s11864-024-01234-z

Martina Catalano, Filippo Nozzoli, Francesco De Logu, Romina Nassini, Giandomenico Roviello

{"title":"Management Approaches for High-Risk Cutaneous Squamous Cell Carcinoma with Perineural Invasion: An Updated Review.","authors":"Martina Catalano, Filippo Nozzoli, Francesco De Logu, Romina Nassini, Giandomenico Roviello","doi":"10.1007/s11864-024-01234-z","DOIUrl":"10.1007/s11864-024-01234-z","url":null,"abstract":"Opinion statement: Cutaneous squamous cell carcinoma (cSCC) stands as the second most prevalent non-melanoma skin cancer worldwide, comprising approximately 20% of all cutaneous malignancies. Determining its precise incidence poses challenges; however, reports indicate a global increase in its prevalence. At the time of diagnosis, the majority of cSCCs are localized, resulting in favorable 5-year cure rates surpassing 90%. Nevertheless, a subset of patients (3-7%) encounters locally advanced or metastatic cSCC, leading to substantial morbidity and mortality. The risk of metastasis ranges from 0.1% to 9.9%, carrying an associated mortality risk of 2.8%. Factors influencing recurrence, metastasis, and disease-specific mortality underscore the significance of perineural invasion (PNI) as a key indicator. Patients with PNI may manifest clinical symptoms and/or radiologic signs of PNI, while the majority remain asymptomatic, and PNI is frequently identified upon histologic examination. Despite its lower frequency compared to other cancer types, PNI serves as a recognized adverse prognostic factor for cSCC. Surgery is the elective treatment for these patients, while the role of adjuvant radiotherapy (ART) is yet contentious and have not been conclusively assessed, particularly in clear surgical margin. Prospective comparative studies are required to comprehensively evaluate the benefit and the risks of ART for cSCC and PNI patients.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"1184-1192"},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modern Management of Gastric Neuroendocrine Neoplasms. 胃神经内分泌肿瘤的现代治疗。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI: 10.1007/s11864-024-01207-2

John W Kunstman, Anil Nagar, Joanna Gibson, Pamela L Kunz

{"title":"Modern Management of Gastric Neuroendocrine Neoplasms.","authors":"John W Kunstman, Anil Nagar, Joanna Gibson, Pamela L Kunz","doi":"10.1007/s11864-024-01207-2","DOIUrl":"10.1007/s11864-024-01207-2","url":null,"abstract":"Opinion statement: Gastric neuroendocrine neoplasms (G-NENs) are a heterogeneous group of tumors that broadly fall into two groups. The first group, driven by oversecretion of gastrin, are generally multifocal, small, and behave indolently with a low (but non-zero) risk of progression and metastatic spread. They are conventionally categorized into type 1, with endogenous gastric-based overproduction of gastrin, and type 2 G-NEN, with overproduction of gastrin from an extra-gastric gastrin-secreting tumor. The second group, termed type 3 G-NEN, occur spontaneously and are potentially more aggressive, having a clinical course analogous to other neuroendocrine tumors of the gastrointestinal tract. Type 1 G-NEN can be managed with endoscopic surveillance and resection of visible lesions with great success, reserving surgery for the rare high-risk lesion, whereas surgical resection of the causative gastrin-secreting tumor in type 2 G-NEN is usually curative. Type 3 G-NEN is usually managed with formal surgical resection but there is growing evidence that limited surgery or even endoscopic resection in appropriately selected patients with low risk is both safe and effective. A novel subtype of G-NEN, associated with long-term proton pump inhibitor usage, is increasing in incidence. The pathophysiology seems to parallel type 1 G-NEN. In the setting of metastatic disease, which can occur in any subtype but is most common by far in type 3 G-NEN, the lack of trial data unique to G-NEN results in extrapolation of strategies and agents for treatment of non-gastric neuroendocrine disease. The rapid pace of development in this area is likely to benefit the metastatic G-NEN patient as well. As treatment is predicate on type of G-NEN, establishing the etiology of the lesion is crucial but growing knowledge of G-NEN pathophysiology and close collaboration between pathologists, gastroenterologists, radiologists, surgeons, and oncologists have enabled a growing trend towards de-escalation and less-invasive treatment paradigms.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"1137-1152"},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141856979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuropathic Pain in Cancer: What Are the Current Guidelines? 癌症患者的神经性疼痛：当前的指导方针是什么？

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-01 Epub Date: 2024-08-05 DOI: 10.1007/s11864-024-01248-7

Matthew R Mulvey, Carole A Paley, Anna Schuberth, Natalie King, Andy Page, Karen Neoh

引用次数: 0

Gastrointestinal Cancer Therapy and Cardiotoxicity. 胃肠道癌症治疗与心脏毒性

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-01 Epub Date: 2024-08-05 DOI: 10.1007/s11864-024-01236-x

Orly Leiva, Talal El Zarif, Jose Alvarez-Cardona

引用次数: 0